查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1413826

细胞治疗市场：按支架、按应用划分 - 2024-2030 年全球预测

Acellular Therapy Market by Scaffold (Cell Laden Hydrogel, Extracellular Matrix (ECM), Fused Deposition Modeling (FDM)), Application (Cardiology, Gastroenterology, Hepatology) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

细胞治疗市场规模预估2023年为110.7亿美元，2024年达124.9亿美元，预计2030年将达到266.5亿美元，复合年增长率为13.37%。

全球细胞治疗市场

主要市场统计
基准年[2023] 110.7亿美元
预测年份 [2024] 124.9亿美元
预测年份 [2030] 266.5亿美元
复合年增长率（%） 13.37%
细胞治疗市场-IMG1

细胞疗法代表再生医学的一个分支，利用细胞成分来修復和再生组织和器官。这些成分包括多种生物分子，如蛋白质、胜肽、生长因子、细胞外基质（ECM）成分和合成的生物活性化合物，但不包括活细胞。该治疗方法利用这些细胞材料的领导潜力来刺激身体的内部修復机制并为组织再生提供支架。 KEYWORD 市场成长受到慢性病盛行率增加、治疗技术进步以及再生医学研究投资增加等因素的影响。此外，政府积极支持再生医学的努力也正在加速细胞疗法的交付。然而，治疗开发的高成本、严格的监管要求以及製造流程的复杂性影响了细胞疗法的开发。细胞治疗市场的潜在机会包括开拓具有增强生物相容性和生物活性的生医材料、与科技公司合作开发先进製造技术以及开拓新兴国家市场。

区域洞察

在美国，特别是美国，细胞疗法已广泛应用于多种临床应用，包括创伤治疗、整形外科治疗以及最近的整容手术。 Acela 疗法在美洲的生产非常复杂，严格的 FDA 法规确保了最高的品质和安全标准。在亚太地区，日本、韩国、中国和印度等国家正成为细胞治疗的重要市场。在这些国家，不断增长的糖尿病人口增加了这些治疗方法在慢性伤口和糖尿病溃疡治疗中的使用。此外，经济成长和医疗保健投资使亚太地区成为新兴的医疗旅游中心，直接影响细胞治疗药物等先进治疗方法的使用。中国和韩国特别投资扩大产能，而日本则以其再生医学创新而闻名。欧洲拥有成熟的细胞治疗市场，拥有用于伤口护理、组织再生和外科应用的先进产品。欧洲是许多大公司的所在地，正在推动该领域的技术创新。中东和非洲部分地区也认识到了蜂窝产品的潜力，但由于广大地区的经济和医疗保健系统不同，其采用情况并不均衡。欧洲国家拥有符合 EMA 指南的强大生产框架，确保高品质生产。德国、英国、英国等生物技术中心拥有强大的生产能力。

FPNV定位矩阵

FPNV定位矩阵对于评估细胞治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对细胞治疗市场供应商的现状进行富有洞察力和深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-细胞治疗市场的市场规模与预测是多少？

2-在细胞治疗市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3-细胞治疗市场的技术趋势和法律规范是什么？

4-细胞治疗市场主要厂商的市场占有率是多少？

5-进入细胞治疗市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病和老龄化相关疾病的盛行率增加
      • 政府推动再生医学和干细胞研究的倡议
      • 提高无细胞和智慧生物材料的可用性
    • 抑制因素
      • 缺乏熟练的研究人员和有限的报销选择
    • 机会
      • 全球细胞治疗与研发的进展
      • 医院和医疗机构承担的细胞治疗计划数量不断增加。
    • 任务
      • 有关再生医学和无细胞疗法的复杂法规
  • 市场区隔分析
    • 支架：优先考虑细胞外基质以支持细胞治疗
    • 应用：开发针对肿瘤部位的细胞疗法
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章 立足细胞治疗市场

  • 含有细胞的水凝胶
  • 细胞外基质（ECM）
  • 熔融沉积建模(FDM)

第七章细胞治疗市场：依应用分类

  • 心臟病学
  • 消化内科
  • 肝病学
  • 神经病学
  • 肿瘤学

第八章美洲细胞治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区细胞治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲细胞治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析
    • 新产品发布和功能增强

第12章竞争产品组合

  • 主要公司简介
    • Allergan Inc. by Abbvie Inc.
    • AlloSource
    • Aziyo Biologics
    • Baxter International
    • Becton, Dickinson and Company
    • BioHorizons, Inc.
    • EnColl Corporation
    • Engitix Ltd
    • Fidia Farmaceutici SpA
    • GSK PLC
    • Humacyte, Inc.
    • In2Bones Global by CONMED Corporation
    • Integra LifeSciences Corporation
    • LifeNet Health
    • MiMedx Group
    • Organicell Regenerative Medicine, Inc.
    • Organogenesis Holdings Inc.
    • Reprise Biomedical, Inc.
    • Sanofi SA
    • Smith & Nephew PLC
    • Stryker Corporation
    • Tissue Regenix
    • Vascudyne, Inc.
    • Zimmer Biomet
  • 主要产品系列

第十三章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-5A3042B3D695

[196 Pages Report] The Acellular Therapy Market size was estimated at USD 11.07 billion in 2023 and expected to reach USD 12.49 billion in 2024, at a CAGR 13.37% to reach USD 26.65 billion by 2030.

Global Acellular Therapy Market

KEY MARKET STATISTICS
Base Year [2023] USD 11.07 billion
Estimated Year [2024] USD 12.49 billion
Forecast Year [2030] USD 26.65 billion
CAGR (%) 13.37%
Acellular Therapy Market - IMG1

Acellular therapy represents a branch of regenerative medicine that utilizes acellular components with the goal of repairing or regenerating tissues and organs. These components can include various biomolecules such as proteins, peptides, growth factors, extracellular matrix (ECM) components, and synthetic bioactive compounds but lack any living cells. This form of therapy harnesses the instructive potential of these acellular materials to stimulate the body's intrinsic repair mechanisms or to provide a scaffold for tissue regeneration. The growth of the acellular therapy market is influenced by factors such as the increasing prevalence of chronic diseases, advancements in treatment technology, and growing investments in regenerative medicine research. Further, favorable government initiatives to support regenerative medicine have also accelerated the provision of acellular therapy. However, the high cost of therapy development, stringent regulatory requirements, and the complexity of the manufacturing process impact the acellular therapy development. Potential opportunities within the acellular therapy market include the development of biomaterials with enhanced biocompatibility and bioactivity, collaboration with technology companies for advanced manufacturing techniques, and exploring untapped markets in developing countries.

Regional Insights

The Americas, particularly the United States, have witnessed widespread adoption of acellular therapy across multiple clinical applications, including wound healing, orthopedic treatments, and, increasingly, cosmetic procedures. The production of acellular therapies in the Americas is highly sophisticated, with stringent FDA regulations ensuring the highest quality and safety standards. In the APAC region, countries such as Japan, South Korea, China, and India are emerging as significant markets for acellular therapy. These countries are seeing increasing use of these therapies in managing chronic wounds and diabetic ulcers due to a growing diabetic population. Further, growing economies and healthcare investments have seen the APAC become a burgeoning medical tourism hub, directly impacting the use of advanced therapies such as acellular therapeutics. China and South Korea are particularly invested in scaling up production capacity, and Japan is known for its innovation in regenerative medicine. Europe has a well-established acellular therapy market, with advanced products used in wound care, tissue regeneration, and surgical applications. The presence of a number of leading companies here drives innovation in the sector. The Middle East and parts of Africa are also recognizing the potential for acellular products; however, their adoption is varied due to differing economic and healthcare systems within the vast region. European countries have robust production frameworks governed by EMA guidelines, which ensure high-quality production. Biotechnology hubs in countries including Germany, the UK, and France have strong production capabilities.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Acellular Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Acellular Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Acellular Therapy Market, highlighting leading vendors and their innovative profiles. These include Allergan Inc. by Abbvie Inc., AlloSource, Aziyo Biologics, Baxter International, Becton, Dickinson and Company, BioHorizons, Inc., EnColl Corporation, Engitix Ltd, Fidia Farmaceutici S.p.A, GSK PLC, Humacyte, Inc., In2Bones Global by CONMED Corporation, Integra LifeSciences Corporation, LifeNet Health, MiMedx Group, Organicell Regenerative Medicine, Inc., Organogenesis Holdings Inc., Reprise Biomedical, Inc., Sanofi S.A., Smith & Nephew PLC, Stryker Corporation, Tissue Regenix, Vascudyne, Inc., and Zimmer Biomet.

Market Segmentation & Coverage

This research report categorizes the Acellular Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Scaffold
    • Cell Laden Hydrogel
    • Extracellular Matrix (ECM)
    • Fused Deposition Modeling (FDM)
  • Application
    • Cardiology
    • Gastroenterology
    • Hepatology
    • Neurology
    • Oncology
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Acellular Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Acellular Therapy Market?

3. What are the technology trends and regulatory frameworks in the Acellular Therapy Market?

4. What is the market share of the leading vendors in the Acellular Therapy Market?

5. Which modes and strategic moves are suitable for entering the Acellular Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Acellular Therapy Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of chronic diseases and age-related conditions
      • 5.1.1.2. Government initiatives to propel regenerative medicine and stem cell research
      • 5.1.1.3. Increased availability of acellular and smart biomaterials
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of skilled research personnel and limited reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and R&D in acellular therapy worldwide
      • 5.1.3.2. Rising number of acellular therapy projects undertaken by hospitals and medical entities
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulations pertaining to regenerative medicine and acellular therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Scaffold: Preference for extracellular matrix to support acellular therapy
    • 5.2.2. Application: Development of acellular therapy designed to target oncology tumor sites
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Acellular Therapy Market, by Scaffold

  • 6.1. Introduction
  • 6.2. Cell Laden Hydrogel
  • 6.3. Extracellular Matrix (ECM)
  • 6.4. Fused Deposition Modeling (FDM)

7. Acellular Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiology
  • 7.3. Gastroenterology
  • 7.4. Hepatology
  • 7.5. Neurology
  • 7.6. Oncology

8. Americas Acellular Therapy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Acellular Therapy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Acellular Therapy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player
    • 11.3.1. New Product Launch & Enhancement
      • 11.3.1.1. Humacyte Announces Positive Top-Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma
      • 11.3.1.2. MTF Biologics to Launch New Acellular Human Reticular Dermal Allograft
      • 11.3.1.3. Humacyte to Provide Human Acellular Vessels (HAVs) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Allergan Inc. by Abbvie Inc.
    • 12.1.2. AlloSource
    • 12.1.3. Aziyo Biologics
    • 12.1.4. Baxter International
    • 12.1.5. Becton, Dickinson and Company
    • 12.1.6. BioHorizons, Inc.
    • 12.1.7. EnColl Corporation
    • 12.1.8. Engitix Ltd
    • 12.1.9. Fidia Farmaceutici S.p.A
    • 12.1.10. GSK PLC
    • 12.1.11. Humacyte, Inc.
    • 12.1.12. In2Bones Global by CONMED Corporation
    • 12.1.13. Integra LifeSciences Corporation
    • 12.1.14. LifeNet Health
    • 12.1.15. MiMedx Group
    • 12.1.16. Organicell Regenerative Medicine, Inc.
    • 12.1.17. Organogenesis Holdings Inc.
    • 12.1.18. Reprise Biomedical, Inc.
    • 12.1.19. Sanofi S.A.
    • 12.1.20. Smith & Nephew PLC
    • 12.1.21. Stryker Corporation
    • 12.1.22. Tissue Regenix
    • 12.1.23. Vascudyne, Inc.
    • 12.1.24. Zimmer Biomet
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ACELLULAR THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. ACELLULAR THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ACELLULAR THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ACELLULAR THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ACELLULAR THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ACELLULAR THERAPY MARKET DYNAMICS
  • FIGURE 7. ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2030 (%)
  • FIGURE 8. ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ACELLULAR THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ACELLULAR THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 6. ACELLULAR THERAPY MARKET SIZE, BY CELL LADEN HYDROGEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ACELLULAR THERAPY MARKET SIZE, BY EXTRACELLULAR MATRIX (ECM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ACELLULAR THERAPY MARKET SIZE, BY FUSED DEPOSITION MODELING (FDM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 10. ACELLULAR THERAPY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ACELLULAR THERAPY MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ACELLULAR THERAPY MARKET SIZE, BY HEPATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ACELLULAR THERAPY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ACELLULAR THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 102. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. ACELLULAR THERAPY MARKET LICENSE & PRICING